Akiladevi Durairaj

Formulierung einer l slichen Famciclovir-Wirkstoffeinlage f r eine neuartige Arzneimittelabgabe, die das nat rliche hydrophile Polymer Hydroxypropylcellulose und das hydrophobe Polymer Ethylcellulose enth lt, unter Verwendung des L sungsmittelgie verfahrens. Erh hte Kontaktzeit, kontrollierte Freisetzung, geringere Verabreichungsh ufigkeit, verbesserte Patientencompliance und gr ere therapeutische Wirksamkeit. Die Formulierung F2, die Famciclovir und 4 mg Hydroxypropylcellulose zwischen Ethylcellulose als Polymer enth lt, erf llt die geforderten pharmazeutischen Eigenschaften von okul ren Einlagen und erwies sich als vielversprechend. Aus der In-vitro-Diffusionsstudie wurde geschlossen, dass die Formulierung F2 im Vergleich zu anderen Formulierungen eine h here Freisetzung von 98,99 % mit kontrollierten Eigenschaften nach 8 Stunden aufwies.

Formula o de um inserto de f rmaco sol vel de famciclovir para uma nova administra o de f rmacos contendo o pol mero hidrof lico natural hidroxipropilcelulose e o pol mero hidrof bico etilcelulose utilizando o m todo de moldagem por solvente. Maior tempo de contacto, liberta o controlada, menor frequ ncia de administra o, maior ades o do doente e maior efic cia terap utica. A formula o F2, que cont m famciclovir e 4 mg de hidroxipropilcelulose ensanduichada entre etilcelulose como pol mero, satisfez as caracter sticas farmac uticas exigidas para os insertos oculares e foi considerada promissora. A partir do estudo de difus o in vitro, concluiu-se que a formula o F2 apresentou uma liberta o superior de 98,99% com caracter sticas controladas s 8 h, quando comparada com outras formula es.

Formulazione di un inserto farmacologico solubile di famciclovir per una nuova somministrazione di farmaci contenente il polimero idrofilo naturale idrossipropilcellulosa e il polimero idrofobo etilcellulosa, utilizzando il metodo di fusione con solvente. Aumento del tempo di contatto, rilascio controllato, riduzione della frequenza di somministrazione, aumento della compliance del paziente e maggiore efficacia terapeutica. La formulazione F2, contenente famciclovir e 4 mg di idrossipropilcellulosa racchiusa tra etilcellulosa come polimero, ha soddisfatto le caratteristiche farmaceutiche richieste per gli inserti oculari ed risultata promettente. Dallo studio di diffusione in vitro, si concluso che la formulazione F2 ha mostrato un rilascio maggiore del 98,99% con caratteristiche controllate a 8 ore rispetto alle altre formulazioni.

Formulation d'un insert m dicamenteux soluble de famciclovir pour une nouvelle administration de m dicaments contenant le polym re hydrophile naturel hydroxypropylcellulose et le polym re hydrophobe thylcellulose en utilisant la m thode de coul e de solvant. Augmentation du temps de contact, lib ration contr l e, diminution de la fr quence d'administration, am lioration de l'observance par le patient et plus grande efficacit th rapeutique. La formulation F2 contenant du famciclovir et 4 mg d'hydroxypropylcellulose pris en sandwich entre l' thylcellulose en tant que polym re r pondait aux caract ristiques pharmaceutiques requises pour les inserts oculaires et s'est av r e prometteuse. L' tude de diffusion in vitro a permis de conclure que la formulation F2 pr sentait une lib ration sup rieure de 98,99 % avec des caract ristiques contr l es pendant 8 heures par rapport aux autres formulations.

Formulation of a soluble drug insert of famciclovir for novel drug delivery containing the natural hydrophilic polymer hydroxypropyl cellulose and hydrophobic polymer ethyl cellulose using the solvent casting method. Increased contact time, controlled release, decreased frequency of administration, increased patient compliance, and greater therapeutic efficacy. Formulation F2 containing famciclovir and 4 mg hydroxy propyl cellulose sandwiched between ethylcellulose as a polymer satisfied the required pharmaceutical characteristics of ocular inserts and was found to be promising. From the in vitro diffusion study, it was concluded that the F2 formulation showed a greater release of 98.99% with controlled characteristics at 8 h when compared to other formulations.

Novel drug delivery and controlled release dosage forms cover a wide range of prolonged action of formulations which provide continuous release of their active ingredients at a predetermined rate and for a predetermined time. The majority of these formulations are designed for oral administration; however, recently such devices have also been introduced for parental administration, ocular insertion and for transdermal application. The most important objective for development of these systems is to furnish an extended duration of action and thus assure greater patient compliance.